Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
Neurocrine-Takeda psychiatry pact suffers another phase 2 fail
Another of the psychiatry drugs Neurocrine licensed from Takeda has stumbled in the clinic.
James Waldron
Nov 11, 2025 6:25am
AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program
Aug 25, 2025 9:42am
HMNC recalibrates precision depression push after phase 2b miss
Aug 5, 2025 10:38am
AbbVie in talks over $1B Gilgamesh buyout: report
Jul 31, 2025 7:48am
Relmada dumps depression asset after slew of phase 3 failures
Jul 11, 2025 12:12pm
Alto's phase 2 depression trial misses primary efficacy endpoint
Jun 26, 2025 9:28am
